F3 and cancer: Thrombosis is the most frequent complication and the second commonest cause of death in patients with malignant disease due to the pathogenesis of blood coagulation activation.1–4 Tumor cell-specific thrombotic secretions such as tissue factor (TF) and cancer procoagulant (CP), microparticles (MPs), and cytokines significantly contribute to the hypercoagulable state and high risk of thrombosis.5–7 Reciprocally, this prothrombotic state parallels the development of malignancy and supports the malignant process by promoting cancer growth, maintenance and propagation.